Ceapro Inc V.CZO

Superb results, recent developments will contribute in 2022

[stockfy]

Superb results, so profitable CZO is dirt-cheap because its current Enterprise Value is only 6 times the adj. EBITDA.  

And we have not seen the contribution from the latest two key developments below, we will see them in this year's results:

1) Ceapro recently appointed top executive from global pharmaceutical industry:

https://themarketherald.ca/ceapro-bolsters-board-of-directors-with-appointment-of-top-executive-from-global-pharmaceutical-industry-2022-03-02/?utm_source=stockhouse.com&utm_medium=widget&utm_campaign=stockhouse.com%7Cwebpart_news%7Cquote_tab


2) Ceapro recently signed Exclusive Long-Term Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise:

https://stockhouse.com/news/press-releases/2022/03/10/ceapro-signs-exclusive-long-term-supply-and-distribution-agreement-with-leading

https://themarketherald.ca/ceapro-signs-exclusive-long-term-supply-and-distribution-agreement-with-leading-global-provider-of-active-ingredients-symrise-2022-03-10/?utm_source=stockhouse.com&utm_medium=widget&utm_campaign=stockhouse.com%7Cwebpart_news%7Cquote_tab

[ZoranSto]

YES, that is correct. I am not sure how much more the symrise agreement will be "new" business. They never broke down what the agreement entails. I would assume it will be more than the previous agreement. On another note does anyone on the board have access to the market depth for the shares....just curious. I think it will take a bit of time for the news to filter down and then I

[Ciao]